slides · global inventory
Title
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 303,780
Current window 221,581-221,610
Pages 10,126
Rows per page 30
Component
221,581-221,610 of 303,780
15
Includes a detailed table of Phase 2 cohorts and a list of study objectives.Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations 1 hit
16
The slide details the transition from the All-Treated Population (N=35) to the NSCLC Response-Evaluable Population (N=21) through back-fill expansion.Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations 1 hit
17
Clinical trial baseline characteristics table.Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations 1 hit
18
Data as of 13 Sep 22. Table lists specific adverse events by grade.Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations 1 hit
19
The chart displays dose-dependent exposure levels exceeding multiple efficacy targets (ROS1 G2032R and Wild Type in CNS and periphery).Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations Beat · TractionLoop · Day In Life1 hit
20
Clinical trial data presentation for NVL-520.Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations Beat · TractionLoop · Day In Life1 hit
21
The chart uses a waterfall plot to visualize clinical efficacy, a standard in oncology drug development.Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations Beat · TractionLoop · Day In Life1 hit
22
The chart is a swimmer plot (a common clinical trial visualization).Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations Beat · TractionLoop · Day In Life1 hit
23
Includes clinical trial data (ORR, tumor shrinkage, allele clearance) for a specific drug candidate.Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations Beat · TractionLoop · Day In Life1 hit
24
Includes patient case study images and clinical trial metrics.Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations Beat · TractionLoop · Day In Life1 hit
25
Includes a timeline of treatments leading up to NVL-520 and radiological evidence of response.Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations 1 hit
30
The slide uses three distinct chart types to demonstrate efficacy, pharmacokinetics, and selectivity.Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations 1 hit
31
The slide compares vehicle control against NVL-655 treatment in both bar chart (multiple models) and line chart (PDX model) formats.Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations 1 hit
32
The slide outlines a clinical trial structure with a dose-escalation phase and specific patient cohorts for Phase 2.Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations 1 hit
34
Includes three distinct charts: a dot plot for IC50, a bar chart for selectivity index, and a bar chart for brain penetrance.Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations 1 hit
35
Nuvalent | Investor Presentation Deck | 39 slidesNuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations 1 hit
37
The slide uses a timeline-style layout to track drug development progress from discovery through clinical phases.Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations 1 hit
38
Includes a molecular structure visualization.Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations 1 hit
39
Nuvalent | Investor Presentation Deck | 39 slidesNuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations 1 hit
03
Nuvectis Pharma | Investor Presentation Deck | 23 slidesNuvectis Pharma | Investor Presentation Deck | 23 slides · Nuvectis Pharma
Pitch deck Investor relations 1 hit
05
The slide uses a timeline-style layout to represent drug development stages.Nuvectis Pharma | Investor Presentation Deck | 23 slides · Nuvectis Pharma
Pitch deck Investor relations 1 hit
06
Nuvectis Pharma | Investor Presentation Deck | 23 slidesNuvectis Pharma | Investor Presentation Deck | 23 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
07
Nuvectis Pharma | Investor Presentation Deck | 23 slidesNuvectis Pharma | Investor Presentation Deck | 23 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
12
Clinical trial NCT05226507 status update.Nuvectis Pharma | Investor Presentation Deck | 23 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
13
Nuvectis Pharma | Investor Presentation Deck | 23 slidesNuvectis Pharma | Investor Presentation Deck | 23 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
14
Nuvectis Pharma | Investor Presentation Deck | 23 slidesNuvectis Pharma | Investor Presentation Deck | 23 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
15
The visualization is a standard kinome tree map used in pharmaceutical research to demonstrate drug selectivity.Nuvectis Pharma | Investor Presentation Deck | 23 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
19
Includes two distinct experimental setups: cell proliferation assays and mouse tumor growth models.Nuvectis Pharma | Investor Presentation Deck | 23 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
20
Clinical trial identifier NCT05873686 is provided.Nuvectis Pharma | Investor Presentation Deck | 23 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
01
Nuwellis | Investor Presentation Deck | 29 slidesNuwellis | Investor Presentation Deck | 29 slides · Nuwellis
Pitch deck Investor relations 1 hit